The Oncology Institute, Inc. (TOI)

The Oncology Institute Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	461.04	393.41	324.24	252.48	203	187.52
Revenue Growth (YoY)	21.67%	21.33%	28.42%	24.37%	8.26%	20.66%
Cost of Revenue	392.73	339.42	264.67	200.39	162.16	150.64
Gross Profit	68.31	54	59.57	52.09	40.85	36.88
Selling, General & Admin	102.39	107.83	113.85	119.69	82.89	41.52
Operating Expenses	109.41	114.12	119.72	124.1	86.23	44.7
Operating Income	-41.11	-60.12	-60.15	-72.01	-45.38	-7.82
Interest Expense	-10.53	-7.5	-6.78	-4.08	-0.32	-0.35
Other Non Operating Income (Expenses)	-14.91	2.82	-0.35	25.9	3.71	-8.72
EBT Excluding Unusual Items	-66.54	-64.8	-67.28	-50.19	-41.99	-16.89
Merger & Restructuring Charges	-	-	-	-	-0.48	1.1
Impairment of Goodwill	-	-	-16.87	-9.94	-	-
Gain (Loss) on Sale of Investments	0.13	0.13	0.24	0.64	-	-
Other Unusual Items	-	-	0.8	59.4	30.87	0.98
Pretax Income	-66.41	-64.66	-83.1	-0.09	-11.6	-14.82
Income Tax Expense	-0.13	-	-0.04	-0.24	-0.67	-0.49
Net Income	-66.28	-64.66	-83.07	0.15	-10.93	-14.32
Preferred Dividends & Other Adjustments	-11.58	-11.66	-15.19	0.08	-0.3	-
Net Income to Common	-54.7	-53.01	-67.88	0.07	-10.63	-14.32
Shares Outstanding (Basic)	86	75	74	73	66	59
Shares Outstanding (Diluted)	86	75	74	81	66	59
Shares Change (YoY)	15.14%	1.76%	-8.51%	21.70%	12.03%	-
EPS (Basic)	-0.64	-0.71	-0.92	0.00	-0.16	-0.24
EPS (Diluted)	-0.64	-0.71	-0.92	-0.21	-0.16	-0.24
Free Cash Flow	-27.53	-30.33	-40.88	-67.29	-35.53	-0.69
Free Cash Flow Per Share	-0.32	-0.40	-0.55	-0.83	-0.54	-0.01
Gross Margin	14.82%	13.73%	18.37%	20.63%	20.12%	19.67%
Operating Margin	-8.92%	-15.28%	-18.55%	-28.52%	-22.36%	-4.17%
Profit Margin	-11.87%	-13.47%	-20.93%	0.03%	-5.24%	-7.64%
Free Cash Flow Margin	-5.97%	-7.71%	-12.61%	-26.65%	-17.50%	-0.37%
EBITDA	-34.09	-53.83	-54.28	-67.6	-42.04	-4.65
EBITDA Margin	-7.39%	-13.68%	-16.74%	-26.77%	-20.71%	-2.48%
D&A For EBITDA	7.02	6.29	5.87	4.41	3.34	3.18
EBIT	-41.11	-60.12	-60.15	-72.01	-45.38	-7.82
EBIT Margin	-8.92%	-15.28%	-18.55%	-28.52%	-22.36%	-4.17%
Revenue as Reported	461.04	393.41	324.24	252.48	203	187.52

Updated Nov 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q